🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hidradenitis Suppurativa (HS)

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% NCT06645821EARLY Phase 11 site📍 Norfolk Virginia Clinical Research, Inc. · Tests: EVO101 A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients NCT06946641Phase 11 site📍 Beijing Shanghai Qilu Pharmaceutical Research and Development Cente… · Tests: QLS12010, Placebo Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population NCT07543419n/a16 sites📍 Ancona📍 Bari📍 Brescia Novartis Pharmaceuticals Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa NCT07828860Phase 111 sites📍 West Lafayette📍 Bowling Green📍 Owensboro Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa NCT06932003Phase 1, Phase 21 site📍 Beijing Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158 Tablets Pelashield™ PainGuard™ vs Restrata® in HS Surgery NCT07316192NA1 site📍 Newark Rutgers, The State University of New Jersey · Tests: Pelashield Painguard A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) NCT06888193Phase 114 sites📍 Santa Monica📍 South Miami📍 Boston UCB Biopharma SRL · Tests: Bimekizumab Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. NCT06895499Phase 1, Phase 21 site📍 Jinan Shanghai Huaota Biopharmaceutical Co., Ltd. · Tests: HB0043, HB0043, HB0043 Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia NCT06785779n/a4 sites📍 Riyadh📍 Jeddah📍 Jeddah Novartis Pharmaceuticals · Tests: Secukinmab Real-world Secukinumab Outcomes in Canadian HS Patients NCT07282015n/a15 sites📍 Calgary📍 Calgary📍 Winnipeg Novartis Pharmaceuticals The Safety and Efficacy of Roflumilast Foam in HS NCT07263230Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Roflumilast 0.3% topical foam A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic NCT07123038n/a10 sites📍 San Francisco📍 Stanford📍 Aurora Sonoma Biotherapeutics, Inc. · Tests: Long Term Safety Monitoring Procedures Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa NCT07109765n/a1 site📍 Beijing Peking Union Medical College · Tests: Secukinumab Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa NCT07689188Phase 21 site📍 Missouri City Harrison Dermatology · Tests: Roflumilast 0.3% topical foam A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa NCT07213973Phase 230 sites📍 Birmingham📍 Phoenix📍 Phoenix Incyte Corporation · Tests: Povorcitinib ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa NCT07783542Phase 215 sites📍 Birmingham📍 Fountain Valley📍 Los Angeles Oruka Therapeutics, Inc. · Tests: ORKA-002, Placebo Global Healthcare Study on Hidradenitis Suppurativa NCT07659769n/a1 site📍 Zurich Julia Tatjana Maul Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI NCT07755670n/a1 site📍 Changsha Second Xiangya Hospital of Central South University · Tests: Routine Biologic Therapy for Hidradenitis Suppurativa A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS NCT07855276Phase 11 site📍 Mayfield Heights Novartis Pharmaceuticals · Tests: LOU064, Placebo Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa NCT07244510Phase 21 site📍 Samsun Sinocelltech Ltd. · Tests: SCT650C 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) NCT07155239Phase 11 site📍 Rosemead Wynn Medical Center · Tests: AviClear Lase Treatment, Sham (No Treatment) An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS NCT07665437Phase 344 sites📍 Birmingham📍 Fort Smith📍 North Little Rock Novartis Pharmaceuticals · Tests: Remibrutinib Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib NCT06855498Phase 3296 sites📍 Birmingham📍 Birmingham📍 Montgomery Incyte Corporation · Tests: povorcitinib A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa NCT07384975Phase 241 sites📍 Phoenix📍 Scottsdale📍 Maitland Navigator Medicines, Inc. · Tests: NAV-240, Placebo to match NAV-240 Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa NCT06926192n/a1 site📍 Nanjing Peking Union Medical College · Tests: Surgery combined with secukinumab Radiotherapy for Refractory Hidradenitis Suppurativa NCT07414550NA2 sites📍 Cherry Hill📍 Philadelphia Thomas Jefferson University · Tests: Radiated axilla A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) NCT07766005Phase 234 sites📍 Birmingham📍 Rogers📍 Irvine Spyre Therapeutics, Inc. · Tests: SPY072, Placebo, bimekizumab Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa NCT07489573Phase 410 sites📍 Guangzhou📍 Shijiazhuang📍 Chengdu Novartis Pharmaceuticals · Tests: Secukinumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy